Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
128.7 USD | -0.48% | -1.59% | +17.69% |
02:36pm | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
May. 13 | Merck: phase 3 trial in melanoma halted | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.69% | 327B | |
+29.30% | 682B | |
+30.34% | 586B | |
-3.23% | 364B | |
+3.67% | 285B | |
+16.17% | 240B | |
+10.13% | 209B | |
-8.55% | 203B | |
+7.79% | 165B | |
-1.30% | 161B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141